Legaz Isabel, Jimenez-Coll Víctor, González-López Rosana, Fernández-González Marina, Alegría-Marcos María José, Galián José Antonio, Botella Carmen, Moya-Quiles Rosa, Muro-Pérez Manuel, Minguela Alfredo, Llorente Santiago, Muro Manuel
Department of Legal and Forensic Medicine, Biomedical Research Institute of Murcia (IMIB), Regional Campus of International Excellence "Campus Mare Nostrum," Faculty of Medicine, University of Murcia (UMU), 30100 Murcia, Spain.
Immunology Service, University Clinical Hospital "Virgen de la Arrixaca"-IMIB, 30120 Murcia, Spain.
Biomedicines. 2024 Jan 5;12(1):116. doi: 10.3390/biomedicines12010116.
Allograft rejection is a widespread complication in allograft recipients with chronic kidney disease. Undertreatment of subclinical and clinical rejection and later post-transplant problems are caused by an imperfect understanding of the mechanisms at play and a lack of adequate diagnostic tools. Many different biomarkers have been analyzed and proposed to detect and monitor these crucial events in transplant outcomes. In this sense, microRNAs may help diagnose rejection or tolerance and indicate appropriate treatment, especially in patients with chronic allograft rejection. As key epigenetic regulators of physiological homeostasis, microRNAs have therapeutic potential and may indicate allograft tolerance or rejection. However, more evidence and clinical validation are indispensable before microRNAs are ready for clinical prime time.
同种异体移植排斥是慢性肾病同种异体移植受者中普遍存在的并发症。对亚临床和临床排斥反应的治疗不足以及移植后后期出现的问题，是由于对其中起作用的机制理解不充分以及缺乏足够的诊断工具所致。人们已经分析并提出了许多不同的生物标志物，以检测和监测移植结果中的这些关键事件。从这个意义上说，微小RNA可能有助于诊断排斥或耐受，并指示适当的治疗方法，尤其是在慢性同种异体移植排斥患者中。作为生理稳态的关键表观遗传调节因子，微小RNA具有治疗潜力，可能指示同种异体移植的耐受或排斥。然而，在微小RNA准备好进入临床应用之前，更多的证据和临床验证是必不可少的。
